Media

William Hearl: ‘If we figure out a way to cure a cancer . . . the money will find us’ William Hearl is founder and chief executive officer of Immunomic

Announces Issuance of Patent Related to LAMP-Vax™ Technology November 22, 2016 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the

THE REMARKABLE SCIENCE BEHIND LAMP TECHNOLOGY – AND ITS POTENTIAL TO TREAT HUMAN DISEASE http://dev.immunomix.com/old/wp-content/uploads/2016/05/Partner_in_Focus_ITI.pdf The body’s own immune system is its best defense against everything from allergies to cancer –

Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration On Tues., Nov. 10, Johns Hopkins University and Immunomic Therapeutics, Inc. celebrated the success of the LAMP-Vax platform. The technology

-Immunomic Therapeutics to receive upfront payment of $300 million plus 10 percent royalties from potential products for allergic diseases, including peanut allergy- -Immunomic Therapeutics to retain rights of LAMP-vax platform

HERSHEY, Pa. and ROCKVILLE, Md., Aug. 28, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that

HERSHEY, Pa. and ROCKVILLE, Md., June 16, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that

HERSHEY, Pa. and ROCKVILLE, Md., June 3, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that

HERSHEY, Pa. and ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that

HERSHEY, Pa. and ROCKVILLE, Md., May 6, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it

HERSHEY, Pa. and ROCKVILLE, Md., May 4, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. (ITI), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it

HERSHEY, Pa. and ROCKVILLE, Md., March 31, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that